Equities
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

EssilorLuxottica SA is a France-based ophthalmic company. The Company designs, distributes, manufactures, and markets a range of lenses, frames, and sunglasses to improve and protect eyesight. It also develops and markets equipment for prescription laboratories and instruments, and services for eye care professionals. It operates through three segments: Lenses and Optical Instruments, which includes corrective lenses, optical instruments intended for opticians and optometrists; Equipment, which includes machines and consumables used by plants and prescription laboratories, and Sunglasses & Readers, which encompasses non-prescription reading glasses and non-prescription sunglasses. EssilorLuxottica's assets include recognized brands, such as Ray-Ban and Oakley for eyewear, Varilux and Transitions for ophthalmic optical technologies, and Sunglass Hut and Lenscrafters for international distribution networks.

  • Revenue in EUR (TTM)25.83bn
  • Net income in EUR2.29bn
  • Incorporated1993
  • Employees193.69k
More ▼

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status
EL:PAR since
announced
Transaction
value
Rhein Vision-Aricestii Rahtivani Lenses FactoryDeal completed10 Sep 202410 Sep 2024Deal completed9.88%--
East Coast-Eyeglass Cases Manufacturing FacilityDeal completed10 Sep 202410 Sep 2024Deal completed9.88%--
Optical Investment Group SAAnnounced30 Jul 202430 Jul 2024Announced11.95%--
Heidelberg Engineering GmbHDeal completed17 Jul 202417 Jul 2024Deal completed16.96%--
Supreme Holdings IncDeal completed17 Jul 202417 Jul 2024Deal completed16.96%1.50bn
Data delayed at least 15 minutes, as of Nov 21 2024 16:35 GMT.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.